Aspiriant LLC’s Abbott ABT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.82M | Buy |
17,719
+981
| +6% | +$111K | 0.05% | 117 |
|
|
2025
Q4 | $2.1M | Sell |
16,738
-315
| -2% | -$40.1K | 0.06% | 106 |
|
|
2025
Q3 | $2.28M | Sell |
17,053
-206
| -1% | -$27K | 0.07% | 92 |
|
|
2025
Q2 | $2.35M | Sell |
17,259
-2,001
| -10% | -$264K | 0.07% | 93 |
|
|
2025
Q1 | $2.55M | Sell |
19,260
-674
| -3% | -$85.8K | 0.09% | 85 |
|
|
2024
Q4 | $2.25M | Sell |
19,934
-384
| -2% | -$44.4K | 0.08% | 91 |
|
|
2024
Q3 | $2.32M | Sell |
20,318
-33
| -0.2% | -$3.62K | 0.09% | 89 |
|
|
2024
Q2 | $2.11M | Sell |
20,351
-752
| -4% | -$79.7K | 0.09% | 87 |
|
|
2024
Q1 | $2.4M | Sell |
21,103
-179
| -0.8% | -$20.5K | 0.1% | 90 |
|
|
2023
Q4 | $2.34M | Sell |
21,282
-298
| -1% | -$29.8K | 0.11% | 86 |
|
|
2023
Q3 | $2.09M | Sell |
21,580
-616
| -3% | -$64.7K | 0.11% | 88 |
|
|
2023
Q2 | $2.42M | Buy |
22,196
+3,080
| +16% | +$328K | 0.12% | 81 |
|
|
2023
Q1 | $1.94M | Sell |
19,116
-113
| -0.6% | -$11.9K | 0.1% | 89 |
|
|
2022
Q4 | $2.11M | Sell |
19,229
-386
| -2% | -$40K | 0.11% | 87 |
|
|
2022
Q3 | $1.9M | Buy |
19,615
+445
| +2% | +$47.4K | 0.09% | 84 |
|
|
2022
Q2 | $2.08M | Buy |
19,170
+102
| +0.5% | +$11.6K | 0.1% | 81 |
|
|
2022
Q1 | $2.26M | Sell |
19,068
-768
| -4% | -$95.2K | 0.12% | 81 |
|
|
2021
Q4 | $2.79M | Buy |
19,836
+1,831
| +10% | +$234K | 0.15% | 73 |
|
|
2021
Q3 | $2.13M | Sell |
18,005
-753
| -4% | -$92.5K | 0.13% | 74 |
|
|
2021
Q2 | $2.17M | Buy |
18,758
+444
| +2% | +$51.8K | 0.12% | 72 |
|
|
2021
Q1 | $2.19M | Sell |
18,314
-754
| -4% | -$89.3K | 0.14% | 64 |
|
|
2020
Q4 | $2.09M | Sell |
19,068
-4,184
| -18% | -$455K | 0.14% | 63 |
|
|
2020
Q3 | $2.54M | Buy |
23,252
+2,550
| +12% | +$259K | 0.2% | 58 |
|
|
2020
Q2 | $1.89M | Sell |
20,702
-1,446
| -7% | -$131K | 0.18% | 57 |
|
|
2020
Q1 | $1.75M | Sell |
22,148
-1,244
| -5% | -$104K | 0.17% | 54 |
|
|
2019
Q4 | $2.03M | Sell |
23,392
-1,261
| -5% | -$106K | 0.19% | 58 |
|
|
2019
Q3 | $2.06M | Sell |
24,653
-889
| -3% | -$75.5K | 0.18% | 73 |
|
|
2019
Q2 | $2.15M | Sell |
25,542
-1,321
| -5% | -$104K | 0.18% | 74 |
|
|
2019
Q1 | $2.15M | Sell |
26,863
-4,722
| -15% | -$351K | 0.18% | 75 |
|
|
2018
Q4 | $2.29M | Sell |
31,585
-497
| -2% | -$34.9K | 0.17% | 75 |
|
|
2018
Q3 | $2.35M | Sell |
32,082
-2,603
| -8% | -$171K | 0.2% | 74 |
|
|
2018
Q2 | $2.12M | Buy |
34,685
+79
| +0.2% | +$4.79K | 0.18% | 77 |
|
|
2018
Q1 | $2.07M | Buy |
34,606
+30,711
| +788% | +$1.85M | 0.18% | 72 |
|
|
2017
Q4 | $222K | Sell |
3,895
-36,649
| -90% | -$2.03M | 0.07% | 75 |
|
|
2017
Q3 | $2.16M | Sell |
40,544
-5,145
| -11% | -$258K | 0.18% | 72 |
|
|
2017
Q2 | $2.22M | Sell |
45,689
-164
| -0.4% | -$7.42K | 0.19% | 74 |
|
|
2017
Q1 | $2.04M | Sell |
45,853
-5,110
| -10% | -$221K | 0.17% | 80 |
|
|
2016
Q4 | $1.96M | Buy |
50,963
+343
| +0.7% | +$13.6K | 0.18% | 76 |
|
|
2016
Q3 | $2.14M | Sell |
50,620
-1,513
| -3% | -$64.8K | 0.21% | 68 |
|
|
2016
Q2 | $2.56M | Sell |
52,133
-1,994
| -4% | -$79.4K | 0.24% | 67 |
|
|
2016
Q1 | $2.26M | Buy |
+54,127
| New | +$2.14M | 0.22% | 66 |
|
Other funds holding ABT
VCM
VPM
Aspiriant LLC's ABT Position: Q1 2026 in Review
Aspiriant LLC increased its Abbott (ABT) stake by 5.9% in Q1 2026, buying an estimated $111K and bringing the position to 17,719 shares worth $1.82M. The position accounts for 0.05% of the portfolio, ranked #117.
Aspiriant LLC first reported a position in ABT in Q1 2016 and has held it in 41 quarters since. The position peaked at $2.79M in Q4 2021. 3,083 funds tracked by Wall St. Rank hold ABT as of Q1 2026.
- Aspiriant LLC held 17,719 shares of Abbott worth $1.82M as of Q1 2026.
- Aspiriant LLC bought 981 Abbott shares in Q1 2026, an estimated $111K.
- Abbott made up 0.05% of Aspiriant LLC's portfolio in Q1 2026, its #117 holding.
- Aspiriant LLC first reported a position in Abbott in Q1 2016 and has held it in 41 quarters since.
- Aspiriant LLC's Abbott position peaked at $2.79M in Q4 2021.
- 3,083 funds tracked by Wall St. Rank held Abbott as of Q1 2026.
Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.